CNS Pharmaceuticals (CNSP) announced John Climaco has stepped down as CEO of CNS Pharmaceuticals and Rami Levin, MBA, has been appointed as President & CEO. Levin will join CNS effective January 1, 2026 following senior leadership roles as President and CEO of Saniona and CEO of ImStem Biotechnology
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNSP:
- CNS Pharmaceuticals Increases Authorized Shares for Growth
- CNS Pharmaceuticals: Promising Drug Pipeline and Strategic Plans Drive Buy Rating
- CNS Pharmaceuticals Reports Financial Gains Amid Ongoing R&D
- CNS Pharmaceuticals reports Q3 EPS ($5.76) vs. ($153.20) last year
- CNS Pharmaceuticals sees cash runway into 2H26